CB
Converge Bio Inc.
SEC filingBiotechnology · Claymont, DE
Amount raised$25Msold at filing
Total offering$25M
Investors in the raise19count reported to the SEC
FiledApr 28, 2026first sale Sep 24, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Shahar TzafrirDirector
Dov GertzExecutive Officer, Director
Oded KalevExecutive Officer, Director
Andrew HedinDirector
Iddo WeinerExecutive Officer
Executive officers, directors and promoters as listed on the Form D.